Catalyst
Slingshot members are tracking this event:
Alder (ALDR) Initiates Phase III PROMISE 1 Trial Evaluating ALD403 for the Prevention of Frequent Episodic Migraines
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALDR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 13, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iii Trial, Promise 1, Frequent Episodic Migraines, Trial Initiation, Ald403
